Publication Name	World Journal of Stem Cells
Manuscript ID	26990
Country	United States

Received	2016-05-03 15:00
Peer-Review Started	2016-05-03 19:05
To Make the First Decision	2016-06-06 11:01
Return for Revision	2016-06-13 14:16
Revised	2016-07-07 02:06
Second Decision	2016-08-16 11:34
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2016-08-29 12:11
Articles in Press	2016-08-29 12:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-10-17 14:16
Publish the Manuscript Online	2016-10-20 21:54

ISSN	1948-0210 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cell Biology
Manuscript Type	Therapeutics Advances
Article Title	Stem cell therapy for the treatment of Leydig cell dysfunction in primary hypogonadism
Manuscript Source	Invited Manuscript
All Author List	Taylor C Peak, Nora M Haney, William Wang, Kenneth J DeLay and Wayne J Hellstrom
Funding Agency and Grant Number
Corresponding Author	Wayne J Hellstrom, MD, Department of Urology, School of Medicine, Tulane University, 1430 Tulane Ave. 8642, New Orleans, LA 70112, United States. whellst@tulane.edu
Key Words	Stem cell therapy; Leydig cells; Primary hypogonadism; Stem Leydig cells; Testosterone; Bone marrow-derived stem cells; Adipose-derived mesenchymal stem cells
Core Tip	Although clinicians are capable of treating primary hypogonadism with exogenous testosterone, there is no therapy that mimics its physiologic release. Two current directions exist for stem cell therapy in male primary hypogonadism. The first method involves differentiating adult Leydig cells from stem cells of various origins from bone marrow, adipose, or embryonic sources. The second method involves isolating, identifying, and transplanting stem Leydig cells (SLCs) into testicular tissue. Re-activation of SLCs in men with primary hypogonadism due to age would also be an alternative method. As researchers are better able to replicate the differentiation process of androgenic tissue, treatments will hopefully follow.
Publish Date	2016-10-20 21:54
Citation	Peak TC, Haney NM, Wang W, DeLay KJ, Hellstrom WJ. Stem cell therapy for the treatment of Leydig cell dysfunction in primary hypogonadism. World J Stem Cells 2016; 8(10): 306-315
URL	http://www.wjgnet.com/1948-0210/full/v8/i10/306.htm
DOI	http://dx.doi.org/10.4252/wjsc.v8.i10.306

Full Article (PDF)	WJSC-8-306.pdf
Full Article (Word)	WJSC-8-306.doc
Manuscript File	26990-Review.docx
Answering Reviewers	26990-Answering reviewers.pdf
Audio Core Tip	26990-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	26990-Conflict-of-interest statement.pdf
Copyright License Agreement	26990-Copyright assignment.pdf
Peer-review Report	26990-Peer-review(s).pdf
Scientific Misconduct Check	26990-Scientific misconduct check.pdf
Scientific Editor Work List	26990-Scientific editor work list.pdf